Bover_EU_Renal.qxp 9/7/07 9:30 am Page 23
Slowing the Progression of Vascular Calcification in Chronic Kidney Disease Patients
chronic renal failure, Circulation, 2002;106(1):100–105. 2007;20(2):158–69. J Kidney Dis, 2005;46(3):464–9.
29. Qnibi WY, Cardiovascular calcification in nondialyzed patients 51. Inoue T, Kawashima H, 1,25-Dihydroxyvitamin D3 stimulates 76. Monney P, Nguyen QV, Perroud H, et al., Rapid improvement of
with chronic kidney disease, Semin Dial, 2007;20(2):134–8. 45Ca2+-uptake by cultured vascular smooth muscle cells calciphylaxis after intravenous pamidronate therapy in a patient
30. Friedman EA, Calcium-Based Phosphate Binders Are derived from rat aorta, Biochem Biophys Res Commun, with chronic renal failure, 2004;19(8):2130–32.
Appropriate in Chronic Renal Failure, Clin J Am Soc Nephrol, 1988;152(3):1388–94. 77. Nitta K, Akiba T, Suzuki K, et al., Effects of cyclic intermittent
2006;1:704–9. 52. Jono S, Nishizawa Y, Shioi A, Morii H, 1,25-Dihydroxyvitamin etidronate therapy on coronary artery calcification in patients
31. Block GA, Klassen PS, Lazarus JM, et al., Mineral metabolism, D3 increases in vitro vascular calcification by modulating receiving long-term hemodialysis, Am J Kidney Dis, 2004;44(4):
mortality, and morbidity in maintenance hemodialysis, J Am Soc secretion of endogenous parathyroid hormone-related peptide, 680–88.
Nephrol, 2004;15(8):2208–18. Circulation, 1998;98(13):1302–6. 78. Price PA, Buckley JR, Williamson MK, The amino
32. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al., Survival 53. Merke J, Hofmann W, Goldsmith D, et al., Demonstration of bisphosphonate ibandronate prevents vitamin D toxicity and
predictability of time-varying indicators of bone disease in 1,25(OH)2 vitamin D3 receptors and actions in vascular smooth inhibits vitamin D-induced calcification of arteries, cartilage,
maintenance hemodialysis patients, Kidney Int, 2006;70(4): muscle cells in vitro, Calcif Tissue Int, 1987;41(2):112–14. lungs and kidneys in rats, J Nutr, 2001;131(11):2910–15.
771–80. 54. Goldsmith DJA, Covic A, Sambrook PA, Ackrill P, Vascular 79. Coco M, Glicklich D, Faugere MC, et al., Prevention of bone
33. Cozzolino M, Staniforth ME, Liapis H, et al., Sevelamer calcification in long-term haemodialysis patients in a single loss in renal transplant recipients: a prospective, randomized
hydrochloride attenuates kidney and cardiovascular unit: a retrospective analysis, Nephron, 1997;77:37–43. trial of intravenous pamidronate, J Am Soc Nephrol,
calcifications in long-term experimental uremia, Kidney Int, 55. Andress DL, Vitamin D in chronic kidney disease: a systemic role 2003;14(10):2669–76.
2003;64(5):1653–61. for selective vitamin D receptor activation, Kidney Int, 2006;(1): 80. Brandenburg WM, Westenfeld R, Ketteler M, The fate of bone
34. Mathew S, Lund RJ, Strebeck F, et al., Reversal of the adynamic 33–43. after renal transplantation, J Nephrol, 2004;17(2):190–204.
bone disorder and decreased vascular calcification in chronic 56. Cardús A, Panizo S, Parisi E, et al., Differential effects of 81. Callister TQ, Raggi P, Cooil B, et al., Effect of HMG-CoA
kidney disease by sevelamer carbonate therapy, J Am Soc vitamin d analogs on vascular calcification, J Bone Miner Res, reductase inhibitors on coronary artery disease as assessed by
Nephrol, 2007;18(1):122–30. 2(6):860–66. electron-beam computed tomography, New Eng J Med,
35. Asmus HG, Braun J, Krause R, et al., Two year comparison of 57. López I, Aguilera-Tejero E, Mendoza FJ, et al., Calcimimetic R- 1998;339(27):1972–8.
sevelamer and calcium carbonate effects on cardiovascular 568 decreases extraosseous calcifications in uremic rats treated 82. Achenbach S, Ropers D, Pohle K, et al., Influence of lipid-
calcification and bone density, Nephrol Dial Transplant, with calcitriol, J Am Soc Nephrol, 2006;17(3):795–804. lowering therapy on the progression of coronary artery
2005;20(8):1653–61. 58. Haffner D, Hocher B, Muller D, et al., Systemic cardiovascular calcification: a prospective evaluation, Circulation, 2002;106(9):
36. Raggi P, James G, Burke SK, et al., Decrease in thoracic disease in uremic rats induced by 1,25(OH)2D3, J Hypertens, 1077–82.
vertebral bone attenuation with calcium-based phosphate 2005;23(5):1067–75. 83. Houslay ES, Cowel SJ, Prescott RJ, et al., Progressive coronary
binders in hemodialysis, J Bone Mineral Res, 2005;20(5): 59. Slatopolsky E, Cozzolino M, Finch JL, Differential effects of 19- calcification despite intensive lipid-lowering treatment: a
764–72. nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on randomised controlled trial, Heart, 2006;92(9):1207–12.
37. Ferreira A, FRazao JM, Faugere MC, et al., Effects of sevelamer calcium and phosphorus in normal and uremic rats, Kidney Int, 84. Oschatz E, Benesch T, Kodras K, et al., Changes of coronary
and calcium carbonate on bone mineralization and turnover in 2002;62(4):1277–84. calcification after kidney transplantation, Am J Kidney Dis,
chronic maintenance haemodialysis patients, Nephrol Dial 60. Wu Wong JR, Noonan W, Ma J, et al., Role of phosphorus and 2006;48(2):307–13.
Transplant, 2006;21(Suppl. 4iv):293 (Abstract). vitamin D analogs in the pathogenesis of vascular calcification, 85. Ayus JC, Mizani MR, Achinger SG, et al., Effects of short daily
38. Qunibi WY, Hootkins RE, McDowell LL, et al., Treatment of J Pharmacol Exp Ther, 2006;318(1):90–98. versus conventional hemodialysis on left ventricular hypertrophy
hyperphosphatemia in hemodialysis patients: The Calcium 61. Mizobuchi M, Finch JL, Slatopolsky E, The effects of calcitriol and inflammatory markers: a prospective, controlled study,
Acetate Renagel Evaluation (CARE Study), Kidney Int, and its analogs on vascular calcification, J Am Soc Nephrol, J Am Soc Nephrol, 16(9):2778–88.
2004;65(5):1914–26. 2006;17:F-SA-DS527. 86. Ammirati AL, Dalboni MA, Cendoroglo M, et al., The
39. Bover J, Ortiz-Herbener F, Ballarin J, et al., New therapy 62. Teng M, Wolf M, Lowrie E, et al., Survival of patients progression and impact of vascular calcification in peritoneal
strategies in secondary hyperparathyroidism on dialysis (I): new undergoing hemodialysis with paricalcitol or calcitriol therapy, dialysis patients, Perit Dial Int, 2007;27(3):340–46.
concepts, new treatments, Nefrologia, 2005;25(Suppl. 2): N Engl J Med, 2003;349(5):446–56. 87. Hruska KA, Mathew S, Davies MR, et al., Connections between
100–108. 63. Teng M, Wolf M, Ofsthun MN, et al., Activated injectable vascular calcification and progression of chronic kidney
40. Nikolov IG, Joki N, Maizel J, et al., Pleiotropic effects of the vitamin D and hemodialysis survival: a historical cohort study, disease: therapeutic alternatives, Kidney Int Suppl, 2005;99:
non-calcium phosphate binder sevelamer, Kidney Int Suppl, J Am Soc Nephrol, 2005;16(4):1115–25. S142–51.
2006;105:S16–23. 64. Tentori F, Hunt WC, Stidley CA, et al., Mortality risk among 88. Price PA, June HH, Buckley JR, et al., Osteoprotegerin inhibits
41. Phan O, Ivanovski O, Nguyen-Khoa T, et al., Sevelamer prevents hemodialysis patients receiving different vitamin D analogs, artery calcification induced by warfarin and by vitamin D,
uremia-enhanced atherosclerosis progression in apolipoprotein Kidney Int, 2006;70(10):1858–65. Arterioscler Thromb Vasc Biol, 21(10):1610–16.
E-deficient mice, Circulation, 2005;112(18):2875–82. 65. Bover J, Ballarin J, Andrés E, et al., New therapy strategies in 89. Shao JS, Cheng SL, Charlton-Kachigian N, et al., Teriparatide
42. Jara A, Felsenfeld AJ, Bover J, et al., Chronic metabolic acidosis secondary hyperparathyroidism on dialysis (II): vitamin D (human parathyroid hormone (1-34)) inhibits osteogenic
in azotemic rats on a high-phosphate diet halts the progression analogues and calcimimetics, Nefrologia, 2005;25(Suppl. 2): vascular calcification in diabetic low density lipoprotein
of renal disease, Kidney Int, 2000;58(3):1023–32. 109–16. receptor-deficient mice, J Biol Chem, 2003;278(50):50195–202.
43. Jara A, Chacon C, Ibaceta M, et al., Effect of ammonium 66. Block GA, Martin KJ, de Francisco AL, et al., Cinacalcet for 90. Wu SY, Zhang BH, Pan CS, et al., Endothelin-1 is a potent
chloride and dietary phosphorus in the azotaemic rat. Part II— secondary hyperparathyroidism in patients receiving regulator in vivo in vascular calcification and in vitro in
Kidney hypertrophy and calcium deposition, Nephrol Dial hemodialysis, New Eng J Med, 2004;350(15):1516–25. calcification of vascular smooth muscle cells, Peptides,
Transplant, 2006;21(4):917–23. 67. Moe SM, Chertow GM , Coburn JW, et al., Achieving NKF- 2003;24(8):1149–56.
44 Suki W, Zabaneh R., Cangiano J, et al., The DCOR-trial – a K/DOQI bone metabolism and disease treatment goals with 91. Motro M, Kirwan BA, de Brouwer S, et al., Tracking coronary
prospective, randomized rial assessing the impact on outcomes cinacalcet HCl, Kidney Int, 2005;67(2):760–71. calcification and atherosclerotic lesions in patients with stable
of sevelamer in dialysis patients, J Am Soc Nephrol, 2005;16: 68. Cunningham J, Danese M, Olson K, et al., Effects of the angina pectoris undergoing nifedipine therapy, Cardiology,
281A (Abstract). calcimimetic cinacalcet HCl on cardiovascular disease, fracture, 2007;107(3):165–71.
45. Qunibi W, Moustafa M, Kessler P, et al., Coronary artery and health-related quality of life in secondary 92. Maniscalco BS, Taylor KA, Calcification in coronary artery
calcification in hemodialysis patients: preliminary results from hyperparathyroidism, Kidney Int, 2005;68(4):1793–1800. disease can be reversed by EDTA-tetracycline long-term
the calcium acetate renagel evaluation-2 (CARE-2) study, J Am 69. Block GA, Calcium, calcimimetics and clinical outcomes, Clin J chemotherapy, Pathophysiology, 2004;11(2):95–101.
Soc Nephrol, 2006;17:TH-PO845 (Abstract). Am Soc Nephrol, 2006;1:170–71. 93. Cassidy MJD, Owen JP, Ellis HA, et al., Renal osteodystrophy
46. Schmermund A, Achenbach S, Budde T, et al., Effect of 70. Foley RN, Li S, Liu J, et al., The fall and rise of and metastatic calcification in long-term continuous ambulatory
intensive versus standard lipid-lowering treatment with parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002, peritoneal dialysis, Q J Med, 1985;54(213):29–48.
atorvastatin on the progression of calcified coronary J Am Soc Nephrol, 2005;16(1):210–18. 94. Pecovnik-Balon B, Kramberger S, Tumoral calcinosis in patients
atherosclerosis over 12 months: a multicenter, randomized, 71. de Francisco AM, Ellis HA, Owen HP, et al., on hemodialysis. Case report and review of the literature, Am J
double-blind trial, Circulation, 2006;113(3):427–37. Parathyroidectomy in chronic renal failure, Q J Med, Nephrol, 1997;17(1):93–5.
47. Wanner C, Krane V, Marz W, et al., Atorvastatin in patients 1985;55(218):289–315. 95. Fernández E, Montoliu J, Successful treatment of massive
with type 2 diabetes mellitus undergoing hemodialysis, N Engl J 72. Meema HE, Oreopoulos DG, deVeber GA, Arterial calcifications uraemic tumoral calcinosis with daily haemodialysis and very
Med, 2005;353(3):238–48. in severe chronic renal disease and their relationship to dialysis low calcium dialysate, Nephrol Dial Transplant, 1994;9(8):
48. Finn WF, SPD 405-307 Lanthanum Study Group, Lanthanum treatment, renal transplant, and parathyroidectomy, Radiology, 1207–9.
carbonate versus standard therapy for the treatment of 1976;121(2):315–21. 96. Yamaguchi T, Sugimoto T, Imai Y, et al., Successful treatment
hyperphosphatemia: safety and efficacy in chronic maintenance 73. DiLeo C, Gallieni M, Bestetti A, et al., Cardiac and pulmonary of hyperphosphatemic tumoral calcinosis with long-term
hemodialysis patients, Clin Nephrol, 2006;65(3):191–202. calcification in a hemodialysis patient: partial regression 4 years acetazolamide, Bone, 1995;16(4 Suppl):247S–250S.
49. Goldsmith D, Ritz E, Covic A, Vascular calcification: a stiff after parathyroidectomy, Clin Nephrol, 2003;59(1):59–63. 97. Bas A, López I, Pérez J, et al., Reversibility of calcitriol-induced
challenge for the nephrologist: does preventing bone disease 74. Sabeel A, Al-Homrany M, Complete resorption of massive soft medial artery calcification in rats with intact renal function,
cause arterial disease?, Kidney Int, 2004;66(4):1315–33. tissue calcification in a hemodialysis patient after J Bone Mineral Res, 2006;21(3):484–90.
50. Covic A, Gusbeth-Tatomir P, Goldsmith DJA, Vascular parathyroidectomy, Am J Nephrol, 2000;20(5):421–4. 98. Adragao T, Pires A, Lucas C, A simple vascular calcification
calcification—a new window on the cardiovascular system: role 75. Bleyer AJ, Burkart J, Piazza M, et al., Changes in cardiovascular score predicts cardiovascular risk in haemodialysis patients,
of agents used to manipulate skeletal integrity, Semin Dial, calcification after parathyroidectomy in patients with ESRD, Am Nephrol Dial Transplant, 2004;19(6):1480–88.
EUROPEAN RENAL DISEASE 2007 23
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74